Saxenda Medicaid Coverage by State Tier: What You'll Pay in 2026

Why Medicaid Coverage Varies So Widely

Medicaid is jointly funded by federal and state governments, but states retain broad authority over which drugs their formularies include. The Social Security Act does not require states to cover weight-loss medications, meaning each of the 50 states and the District of Columbia sets its own policy. A 2023 CMS analysis confirmed that obesity pharmacotherapy coverage across state Medicaid programs remains highly inconsistent.

The Federal Coverage Gap

The FDA approved Saxenda in December 2014 based on the SCALE Obesity and Prediabetes trial (N=3,731), in which liraglutide 3 mg produced a mean weight loss of 8.0% vs. 2.6% for placebo at 56 weeks (P<0.001, NEJM 2015). Despite that evidence, Congress has never mandated Medicaid coverage for anti-obesity drugs. The result: a patient in California may pay nothing; a patient in Texas may pay full retail price.

How States Set Their Formularies

States contract with pharmacy benefit managers and Managed Care Organizations to negotiate drug lists. Anti-obesity agents are often placed in non-preferred or excluded status because of high list prices, budget pressure, and a historical misclassification of obesity as a lifestyle choice rather than a chronic disease. The Endocrine Society's 2023 clinical practice guideline explicitly states that obesity is "a chronic, relapsing disease process" requiring sustained pharmacological treatment, yet formulary policy has not kept pace with that clinical consensus. (Endocrine Society, J Clin Endocrinol Metab, 2023)

The Three-Tier State Framework for Saxenda Coverage

States fall into three broad tiers based on how they handle anti-obesity drugs in Medicaid. These tiers are not official CMS designations; they represent a practical classification based on formulary data current as of January 2026.

Tier 1: Covered With Prior Authorization (Approximately 15 States)

These states include Saxenda on their preferred drug list or non-preferred list with an attainable prior-authorization pathway. The typical criteria are:

• Adult BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, or obstructive sleep apnea)
• Documented failure of a supervised diet and exercise program for 3 to 6 months
• Prescriber attestation from a physician, PA, or NP
• No active eating disorder diagnosis
• Reassessment at 16 weeks: if weight loss is <4%, coverage may lapse

States in this group include California (Medi-Cal), New York (Medicaid FFS), Illinois, Washington, Oregon, Colorado, Minnesota, Maryland, Massachusetts, Connecticut, Vermont, Hawaii, New Mexico, and the District of Columbia. Copays for most Medicaid beneficiaries in these states range from $0 to $4 per fill under standard cost-sharing rules.

The SCALE Maintenance trial (N=422) showed that patients who regained weight after stopping liraglutide 3 mg regained significantly more than those who continued, underscoring the clinical need for uninterrupted coverage. (Wiley/Obesity, 2016)

Tier 2: Covered Only for Diabetes or Comorbid Diagnoses (Approximately 20 States)

These states cover liraglutide but only under the Victoza 1.2/1.8 mg label (type 2 diabetes) or through specific managed-care carve-outs. If your primary diagnosis is obesity without diabetes, coverage is denied or requires an appeal.

States in this group commonly include Florida, Georgia, Ohio, Michigan, Pennsylvania, Arizona, Nevada, Virginia, North Carolina, South Carolina, Tennessee, Kentucky, Indiana, Wisconsin, Missouri, Louisiana, Arkansas, Oklahoma, Kansas, and Nebraska.

Patients in Tier 2 states who do have a concurrent type 2 diabetes diagnosis should work with their prescriber to document that diagnosis clearly. Medicaid MCOs in these states sometimes process liraglutide at the 1.8 mg diabetes dose but deny the 3 mg obesity dose on the same claim. A 2020 JAMA Internal Medicine analysis found that among low-income adults eligible for GLP-1 therapy, out-of-pocket cost was the single strongest predictor of non-adherence. (JAMA Intern Med, 2020)

Tier 3: Excluded (Approximately 15 States)

These states have explicit statutory or regulatory exclusions for anti-obesity drugs. Saxenda will not appear on any preferred or non-preferred formulary tier. Appeals are rarely successful unless the prescriber can document a rare metabolic indication unrelated to BMI.

States commonly in this group include Texas, Georgia (for some MCOs), Alabama, Mississippi, Idaho, Wyoming, Montana, South Dakota, North Dakota, West Virginia, New Hampshire, Maine (limited MCOs), Iowa, Utah, and Alaska. Policies shift: Georgia, for example, has moved portions of its Medicaid population to managed care contracts that differ from fee-for-service coverage.

If you are in a Tier 3 state, the most viable paths are Novo Nordisk's patient assistance programs, commercial savings cards, or switching to an alternative GLP-1 agent with broader Medicaid coverage in your state.

Prior Authorization Requirements in Detail

Prior authorization (PA) is the most common barrier even in Tier 1 states. Understanding the exact documentation needed reduces denial rates.

Required Documentation Checklist

1. Height, weight, and calculated BMI documented in the chart on the date of the PA request
2. ICD-10 code: E66.09 (morbid obesity due to excess calories) or E66.01 (morbid obesity, severe), or E11 codes for type 2 diabetes if applicable
3. A structured weight-loss program attempt of at least 90 days, with provider notes or a program completion certificate
4. Medication reconciliation showing no concurrent orlistat, phentermine/topiramate, naltrexone/bupropion, or semaglutide 2.4 mg prescription (most states prohibit concurrent anti-obesity drug therapy)
5. Prescriber's NPI and DEA number
6. Baseline HbA1c if diabetes is a listed comorbidity

Common Denial Reasons and Fixes

The three most frequent denial codes for Saxenda in Medicaid are: (1) "insufficient documentation of diet failure," (2) "drug not covered for primary obesity without comorbidity," and (3) "step therapy required, try orlistat first."

For denial type 3, note that orlistat is covered by nearly all state Medicaid programs and costs under $25 per month. Documenting a 90-day orlistat trial with provider notes clears this step-therapy hurdle in most cases. The FDA's approved prescribing information for Saxenda specifies that it should be used "as an adjunct to a reduced-calorie diet and increased physical activity," so any PA letter should echo that language verbatim. (FDA Saxenda Prescribing Information)

How to Get Saxenda Cheaper: Four Strategies That Work in 2026

For patients in Tier 2 or Tier 3 states, or those awaiting PA approval, four evidence-supported cost-reduction pathways exist.

1. Novo Nordisk Patient Assistance Program

The Novo Nordisk Patient Assistance Program provides Saxenda at no cost to uninsured or underinsured patients with household income at or below 400% of the federal poverty level. The 2026 FPL threshold for a single-person household is $15,060, making 400% equal to $60,240. Applications are submitted through NovoCare (1-866-310-7549) and require a prescriber signature. Processing takes 7 to 14 business days.

2. Saxenda Savings Card (Commercially Insured Patients)

Novo Nordisk offers a savings card for commercially insured patients that reduces out-of-pocket costs to as low as $25 per 30-day supply for eligible patients. This card does not work for Medicaid beneficiaries by federal law (anti-kickback statute prohibitions on manufacturer coupons for government-insured patients).

3. 340B Drug Pricing Program

Federally Qualified Health Centers (FQHCs) and certain hospital outpatient departments participate in the 340B program, which lets covered entities purchase drugs at a steep discount and pass savings to uninsured or underinsured patients. The Health Resources and Services Administration (HRSA) reports that over 12,500 covered entity sites participate in 340B as of 2025. (HRSA 340B Program) A Saxenda pen that costs $330 at retail may cost under $60 through a 340B pharmacy for a qualifying patient.

4. HSA and FSA Accounts

Saxenda qualifies as a deductible medical expense under IRS Publication 502 because it is an FDA-approved prescription medication. Paying with a Health Savings Account (HSA) or Flexible Spending Account (FSA) effectively reduces the cost by your marginal tax rate. For a patient in the 22% federal bracket, a $1,400 monthly Saxenda expense costs roughly $1,092 after the tax offset. HSA funds roll over indefinitely; FSA funds are subject to the use-it-or-lose-it rule with a 2026 carryover limit of $660.

Clinical Outcomes That Support Coverage Decisions

Payers and appeals officers respond to outcome data. Knowing the trial numbers strengthens a PA letter or formal appeal.

SCALE Obesity and Prediabetes Trial

The key SCALE Obesity and Prediabetes trial enrolled 3,731 adults with BMI ≥30 or BMI ≥27 with dyslipidemia or hypertension. At 56 weeks, liraglutide 3 mg produced a mean weight reduction of 8.4 kg (8.0%) vs. 2.8 kg (2.6%) for placebo. More importantly for payer arguments, 63.2% of liraglutide patients lost at least 5% of body weight vs. 27.1% of placebo patients (NEJM, 2015). A 5% weight loss threshold is associated with clinically meaningful improvements in blood pressure, triglycerides, and fasting glucose.

SCALE Diabetes Trial

The SCALE Diabetes trial (N=846) enrolled adults with type 2 diabetes and BMI ≥27. Liraglutide 3 mg reduced body weight by 6.0% vs. 2.0% for placebo at 56 weeks and lowered HbA1c by 1.3 percentage points. (Lancet, 2015) For Tier 2 state patients who have diabetes, this trial is the strongest evidence base for a PA request at the 3 mg dose.

Cardiovascular and Comorbidity Data

A 2023 BMJ meta-analysis of GLP-1 receptor agonists (including liraglutide) confirmed reductions in major adverse cardiovascular events (MACE) of roughly 12% vs. Placebo across pooled trials. (BMJ, 2023) Using cardiovascular risk reduction as a secondary argument in a PA appeal can shift the framing from "cosmetic weight loss" to medically necessary cardiovascular risk management.

Filing a Medicaid Appeal: Step-by-Step

A PA denial is not final. Federal Medicaid law requires states to offer a fair hearing process, and the Centers for Medicare and Medicaid Services (CMS) mandates resolution within 90 days for standard appeals and 72 hours for expedited appeals.

Gathering Evidence for the Appeal Letter

Your prescriber's appeal letter should include:

1. The patient's BMI and documented comorbidities with ICD-10 codes
2. A summary of prior weight-loss interventions (diet, exercise, orlistat if applicable)
3. Citation of the FDA-approved indication and SCALE trial data
4. A statement that obesity meets the Endocrine Society's 2023 definition of a chronic relapsing disease requiring pharmacological management
5. A request for peer-to-peer review with the plan's medical director if available

The Endocrine Society guideline states: "We recommend pharmacotherapy for patients with obesity who have not achieved clinically meaningful weight loss after comprehensive lifestyle intervention." (J Clin Endocrinol Metab, 2023) Quoting that recommendation directly in an appeal letter shifts the burden to the plan to explain why it is departing from a major society guideline.

What Happens After the Appeal

If the internal appeal fails, patients can request a State Fair Hearing through their state Medicaid agency. Legal aid organizations in most states provide free assistance with Medicaid fair hearings. If a fair hearing also fails, patients in states with federally facilitated exchanges can escalate to the CMS Medicaid Integrity Group, though this path is slow.

State-by-State Quick Reference Table

| State | Tier | Typical Copay | PA Required | Step Therapy | |-------|------|---------------|-------------|--------------| | California (Medi-Cal) | 1 | $0, $1 | Yes | No | | New York | 1 | $0, $3 | Yes | No | | Illinois | 1 | $0, $4 | Yes | No | | Washington | 1 | $0, $3 | Yes | No | | Colorado | 1 | $0, $4 | Yes | No | | Florida | 2 | $0 (diabetes only) | Yes | Yes | | Ohio | 2 | $0 (diabetes only) | Yes | Yes | | Michigan | 2 | $0 (diabetes only) | Yes | Yes | | Pennsylvania | 2 | $3 (diabetes only) | Yes | Yes | | Arizona | 2 | $0 (diabetes only) | Yes | Yes | | Texas | 3 | Not covered | N/A | N/A | | Alabama | 3 | Not covered | N/A | N/A | | Idaho | 3 | Not covered | N/A | N/A | | Wyoming | 3 | Not covered | N/A | N/A | | Mississippi | 3 | Not covered | N/A | N/A |

Policies change. Verify current formulary status through your state Medicaid agency's drug look-up tool before prescribing or filling.

Saxenda vs. Semaglutide 2.4 mg: Which Has Better Medicaid Coverage in 2026?

Semaglutide 2.4 mg (Wegovy) was approved by the FDA in June 2021 and produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) vs. 2.4% for placebo (NEJM, 2021). Its superior efficacy and the SELECT cardiovascular outcomes trial (N=17,604, 20% MACE reduction) (NEJM, 2023) have prompted some states to add Wegovy while others have not yet acted.

As of January 2026, Saxenda and Wegovy have similar Medicaid tier distributions nationally, though a handful of Tier 2 states have moved Wegovy to Tier 1 based on the cardiovascular outcome data. A patient currently in a Tier 3 state for Saxenda should ask their prescriber whether their state Medicaid plan has a separate Wegovy coverage policy, because those are adjudicated under a different drug code (NDC 00169-4821-11 for Wegovy vs. 00169-3696-12 for Saxenda).